NanoViricides, Inc. (NYSE American: NNVC) will present updates on its antiviral drug pipeline and platform technologies at the PODD 2025 Conference on October 27, 2025, in Boston. President and Executive Chairman Anil R. Diwan, PhD, will deliver the presentation in Track 5A at the Westin Copley Hotel, providing crucial insights into the company's clinical-stage development programs.
The company's lead candidate, NV-387, represents a significant advancement in antiviral therapy as it progresses toward Phase II clinical trials for multiple indications. The drug candidate is being developed for treatment of MPox and various respiratory viral infections, with preclinical studies demonstrating strong efficacy against respiratory syncytial virus (RSV), Influenza A, and Coronaviruses. This broad-spectrum approach addresses a critical gap in current antiviral treatments, which typically target specific viruses rather than multiple viral families.
NanoViricides' technology platform is based on intellectual property licensed from TheraCour Pharma, Inc., as detailed in their Memorandum of Understanding available at https://www.nanoviricides.com. The company's nanoviricide technology creates special purpose nanomaterials designed to prevent viral escape, a common challenge in antiviral drug development where viruses mutate to resist treatment. This innovative approach could potentially transform how viral infections are treated, particularly for emerging threats where rapid development of effective treatments is essential.
Beyond NV-387, the company is developing NV-HHV-1 for shingles treatment and maintains an extensive pipeline targeting numerous viral diseases including oral and genital herpes, viral eye diseases, various influenza strains, HIV, Hepatitis C, and emerging threats like Ebola virus. The company holds exclusive perpetual licenses for multiple viral disease treatments through its relationship with TheraCour, which licenses the underlying nanomedicine technology from AllExcel.
The presentation at PODD 2025 comes at a critical time for global health security, as the world continues to face threats from respiratory viruses and emerging pathogens. The company's platform technology offers potential advantages for pandemic preparedness by enabling development of broad-spectrum antivirals that could be deployed rapidly against new viral threats. However, the company notes that drug development remains lengthy and capital-intensive, with no guarantee that current candidates will prove sufficiently effective and safe for human clinical development.
Investors and industry observers can access additional information through the company's newsroom at https://ibn.fm/NNVC. The PODD conference presentation will provide important updates on the company's progress toward IND filings and clinical trial initiation, though specific timelines remain dependent on external collaborators and consultants. The development of effective broad-spectrum antivirals represents a crucial frontier in infectious disease treatment, potentially offering more robust defenses against future viral outbreaks and pandemics.
